Fluorodeoxyglucose F18

• 

  Subject Areas on Research

  • (18)F-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis. 
  • (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 
  • 18-Fluorodeoxyglucose positron emission tomography in children and adolescents with traumatic brain injury. 
  • 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • 2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. 
  • A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A systematic review of the factors affecting accuracy of SUV measurements. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. 
  • Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer. 
  • Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. 
  • Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. 
  • Alumina Depyrogenates F 18 Fludeoxyglucose Injection during Purification Processes. 
  • Alzheimer disease: operating characteristics of PET--a meta-analysis. 
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 
  • Anatomical loci of HIV-associated immune activation and association with viraemia. 
  • Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study. 
  • Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. 
  • Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. 
  • Association of heat production with 18F-FDG accumulation in murine brown adipose tissue after stress. 
  • Attenuation correction in hybrid positron emission tomography. 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Cerebral imaging of decompression injury patients with 18-F-2-fluoro-2-deoxyglucose positron emission tomography. 
  • Clinical application of PET for the evaluation of brain tumors. 
  • Clinical oncologic positron emission tomography: an introduction. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. 
  • Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. 
  • Colonic schwannoma visualized on FDG PET/CT. 
  • Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. 
  • Combined positron emission tomography - computed tomography improves specificity for thyroid carcinoma by identifying vocal cord activity after laryngeal nerve paralysis. 
  • Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. 
  • Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging. 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. 
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. 
  • Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. 
  • Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. 
  • Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 
  • Diagnosing pulmonic valve infective endocarditis with positron emission tomography-CT. 
  • Diagnosis of pancreatic carcinoma: role of FDG PET. 
  • Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study. 
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
  • Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. 
  • Early recognition of Alzheimer's disease: what is consensual? What is controversial? What is practical? 
  • Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 
  • Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. 
  • Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET. 
  • Evaluation of primary pulmonary carcinoid tumors using FDG PET. 
  • FDG PET imaging in patients with pathologically verified dementia. 
  • FDG PET of pleural effusions in patients with non-small cell lung cancer. 
  • FDG PET/CT Imaging of Prostate Carcinosarcoma. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. 
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. 
  • FDG-PET finding in early-phase Takayasu arteritis. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. 
  • FDG-PET imaging in patients with pulmonary carcinoid tumor. 
  • FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. 
  • FDG-PET in pediatric posterior fossa brain tumors. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. 
  • FDG-PET/CT characterization of adrenal nodules: diagnostic accuracy and interreader agreement using quantitative and qualitative methods. 
  • False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. 
  • Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. 
  • Focal cerebral metabolic abnormality in a patient with continuous spike waves during slow-wave sleep. 
  • Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. 
  • Fortuitous detection of papillary carcinoma of the thyroid with F-18 FDG positron emission tomography in a patient with non-Hodgkin lymphoma. 
  • Gangliogliomas: characterization by registered positron emission tomography-MR images. 
  • Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. 
  • Gated 99mTc-tetrofosmin and 18F-FDG studies: a comparison of single-acquisition and separate-acquisition protocols. 
  • Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. 
  • Human herpesvirus 6 limbic encephalitis after stem cell transplantation. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. 
  • Imaging biomarker roadmap for cancer studies. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions. 
  • Impact of PET staging in limited-stage small-cell lung cancer. 
  • Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions. 
  • In vivo noninvasive detection of Brown Adipose Tissue through intermolecular zero-quantum MRI. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. 
  • Incidental Thyroid Nodules at Non-FDG PET Nuclear Medicine Imaging: Evaluation of Prevalence and Malignancy Rate. 
  • Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. 
  • Influence of filter choice on 18F-FDG PET segmentation accuracy determined using generalized estimating equations. 
  • Influenza vaccine and FDG-PET. 
  • Integrating PET and CT information to improve diagnostic accuracy for lung nodules: A semiautomatic computer-aided method. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interpretation variability of 18FDG-positron emission tomography studies in dementia. 
  • Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 
  • Is chronically dysfunctional yet viable myocardium distal to a severe coronary stenosis hypoperfused? 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery. 
  • Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 
  • Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. 
  • Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. 
  • Kaposi sarcoma after bilateral lung transplantation. 
  • Limbic encephalitis: comparison of FDG PET and MR imaging findings. 
  • Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment. 
  • Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Low doses of alcohol substantially decrease glucose metabolism in the human brain. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Lung cancer and positron emission tomography with fluorodeoxyglucose. 
  • Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. 
  • Malignant catatonia secondary to sporadic encephalitis lethargica. 
  • Management of Incidental Pituitary Findings on CT, MRI, and 18F-Fluorodeoxyglucose PET: A White Paper of the ACR Incidental Findings Committee. 
  • Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. 
  • Medullary thyroid cancer: early detection and novel treatments. 
  • Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. 
  • Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. 
  • Metastatic melanoma to the heart. 
  • Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Molecular imaging in Alzheimer's disease. 
  • Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Neuroimaging in infantile autism. 
  • Neuronal migration disorders: positron emission tomography correlations. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Normal brain F-18 FDG-PET and MRI anatomy. 
  • Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. 
  • PET and brain tumor image fusion. 
  • PET appearance of tuberculous empyema necessitans. 
  • PET imaging in patients with bronchioloalveolar cell carcinoma. 
  • PET tracers for osteosarcoma. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET-CT evaluation of 2-deoxy-2-[18F]fluoro-D-glucose myocardial uptake: effect of respiratory motion. 
  • PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PET/CT: artifacts caused by bowel motion. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. 
  • Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. 
  • Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. 
  • Positron emission tomography detection of metastatic penile squamous cell carcinoma. 
  • Positron emission tomography diagnosis of Alzheimer's disease. 
  • Positron emission tomography imaging in the thorax. 
  • Positron emission tomography imaging of brain tumors. 
  • Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Positron emission tomography scanning in malignant melanoma. 
  • Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. 
  • Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. 
  • Positron emission tomography: brain tumors and lung cancer. 
  • Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. 
  • Primary muscle lymphoma: clinical and imaging findings. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. 
  • Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. 
  • Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prospective investigation of positron emission tomography in lung nodules. 
  • Pulmonary abnormalities and PET data analysis: a retrospective study. 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. 
  • Recent developments in predicting thyroid malignancy. 
  • Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. 
  • Recommendations on the use of 18F-FDG PET in oncology. 
  • Regional brain activity correlates of nicotine dependence. 
  • Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. 
  • Relation between QT dispersion and myocardial viability in ischemic cardiomyopathy. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. 
  • Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. 
  • Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. 
  • Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. 
  • Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. 
  • T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. 
  • Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. 
  • Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. 
  • Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. 
  • Thallium-201 uptake in lung cancer. 
  • The clinical syndrome of early-life bilateral hippocampal sclerosis. 
  • The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. 
  • The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. 
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. 
  • The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. 
  • The role of PET scanning in the detection of recurrent cervical cancer. 
  • The synthesis of 2-[F-18]fluoro-2-deoxy-D-glucose using glycals: a reexamination. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. 
  • Thoracic FDG PET: state of the art. 
  • Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. 
  • Transmission scanning system for a gamma camera coincidence scanner. 
  • Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Utility of FDG PET/CT in inflammatory cardiovascular disease. 
  • Validation of consensus panel diagnosis in dementia. 
  • Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. 
  • Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. 
  • [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. 
  • [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology
  • Hoang, Jenny K., Associate Professor of Radiology, Radiology, Neuroradiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moon, Richard Edward, Professor of Anesthesiology, Medicine, Pulmonary, Allergy, and Critical Care Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Patz Jr., Edward F., James and Alice Chen Professor of Radiology, Pathology
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology